Cryoport Continues to Strengthen Sales Team with Appointments of Colin Coffua as Vice President, Strategic Accounts and John Phillips as Executive Director, Consulting Services

IRVINE, Calif., July 13, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced it has strengthened its sales team with the appointments of Colin Coffua as Vice President, Strategic Accounts and John Phillips as Executive Director, Consulting Services.

Colin Coffua, an industry veteran with 37 years experience in pharmaceutical related sales and marketing, will drive sales efforts for Cryoport's key strategic account initiatives including key biopharmaceutical companies and clinical research organizations. Mr. Coffua joins Cryoport from inVentiv Health, Inc. where he served as Senior Vice President, Strategic Accounts in the Clinical Division for the past eight years.  In this position, he was responsible for the development and execution of inVentiv Health's global clinical development sales and strategy, and executive relationships for pharmaceutical clients such as Pfizer, Johnson & Johnson, Merck & Company, Daiichi Sankyo, Takeda, Mallinckrodt, Plc and other strategic clients. He achieved new sales of over $250 million across these clients in his last 36 months, exceeding his sales plan by approximately 200%. Previously, Mr. Coffua served as Vice President, Global Account Management at i3 Global, Ingenix, a subsidiary of UnitedHealth Group, prior to its acquisition by inVentiv Health in 2011. His previous experience also includes senior marketing roles at Clinsys Clinical Research, Inc, PAREXEL International, eResearch Technology and Araccel Corporation. Mr. Coffua's extensive sales and marketing experience covers the pharmaceutical and medical device industries having worked with Baxter Healthcare, American Hospital Supply, Boehringer-Ingelheim and Alpha Therapeutic Corporation. He is a graduate of Norwich University, and served as a Captain in the U.S. Army Rangers. He received his MBA in Marketing prior to beginning his career in healthcare.

Jerrell Shelton, Chief Executive Officer of Cryoport, stated, "We are pleased to welcome Colin to our Cryoport team where he will focus on growing revenue by winning larger, strategic accounts, predominantly in biopharma and clinical research organizations. Colin is a highly effective manager with a demonstrable track record in building and maintaining business relationships with some of the world's largest biopharma companies. His strong industry network will be of great assistance as he spearheads our efforts to further penetrated the life sciences industry with our advanced cold chain logistics solutions."

Colin Coffua, Vice President, Strategic Accounts, commented, "Cryoport's suite of cold chain logistics solutions for the life sciences is by far and away the best on the market and fills a growing need in the regenerative medicine space, where some of the world's largest biopharma companies are developing therapies to combat a diverse range of diseases ranging from from Parkinson's Disease to cancer. I am delighted to have the opportunity to work with Cryoport and to help educate the market about our unique offerings and to significantly expand our client base."

In the role of Executive Director, Consulting Services, John Phillips will work to establish Cryoport's Temperature Controlled Logistics Consulting Division, assisting life sciences partners in devising and implementing strategies for dependable global logistics and tailored to their individual needs. Mr. Phillips has more than 30 years experience in sales and development of technology services, with his primary expertise in the consulting and outsourcing services marketplace. Prior to joining Cryoport, Mr. Phillips was with Windstream Communications where he was responsible for the leadership, strategic direction and management of Windstream's Enterprise Managed Services. In this position he delivered profitable, top line revenue growth by developing and executing effective market strategies. Prior to Windstream Communications, Mr. Phillips worked in sales leadership and managed services at CBIZ where he architected key business policies and alliances that facilitated strong revenue growth.  Mr. Phillips began his career with Xerox Corporation where he successfully served in various sales and business development positions.

Jerrell Shelton, Chief Executive Officer of Cryoport, stated, "Since its launch in 2016, our Temperature Controlled Logistics Consulting Service has provided much-needed logistics planning services to life sciences companies as they developed clinical-stage therapies. As our clients move closer to commercializing their regenerative therapies and face increasingly complex logistics requirements, the need for strategic planning in logistics management has become even more evident. John brings an acute understanding of managed services business and an expansive knowledge of services led selling. We are looking forward to John's contributions as he supports Cryoport's clients through our consulting business."

John Phillips, Executive Director, Consulting Services, commented, "Increasingly, life sciences companies are developing strategies for global cold chain logistics management, including contingency options to protect their valuable, and often irreplaceable, biological commodities during transportation. Cryoport is the globally recognized leader in this space and enjoys having the world's foremost regenerative medicine developers on its client roster. I am excited to work to grow Cryoport's consultancy business."

About Cryoport, Inc.

Cryoport is the life sciences industry's most trusted global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.

Cryoport is dedicated to

• simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting;
• delivering the most advanced temperature controlled logistics solutions for the life sciences industry; and
• providing vital information that provides peace of mind throughout the life of each logistics process.

For more information, visit www.cryoport.com. Sign up to follow @cryoport on Twitter at www.twitter.com/cryoport.

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the Transition Report on Form 10-K for the nine months ended December 31, 2016 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

SOURCE Cryoport, Inc.

Related Links

http://www.cryoport.com